Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan

L. B. Twiggs, C. P. Morrow

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20%) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30%) had severe or life-threatening leukopenia with two of four (50%) complicated by septicemia. In Piver's group six of eight patients (75%) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.

Original languageEnglish
Pages (from-to)1369-1371
Number of pages3
JournalCancer Treatment Reports
Volume61
Issue number7
StatePublished - Dec 1 1977

Fingerprint

Melphalan
Cyclophosphamide
Carcinoma
Leukopenia
Therapeutics
Sepsis
Drug Therapy
Dactinomycin
Drug-Related Side Effects and Adverse Reactions
Methotrexate
Fluorouracil
Ovarian Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan. / Twiggs, L. B.; Morrow, C. P.

In: Cancer Treatment Reports, Vol. 61, No. 7, 01.12.1977, p. 1369-1371.

Research output: Contribution to journalArticle

@article{dccb964539f842df871626ca3818d650,
title = "Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan",
abstract = "The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20{\%}) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30{\%}) had severe or life-threatening leukopenia with two of four (50{\%}) complicated by septicemia. In Piver's group six of eight patients (75{\%}) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.",
author = "Twiggs, {L. B.} and Morrow, {C. P.}",
year = "1977",
month = "12",
day = "1",
language = "English",
volume = "61",
pages = "1369--1371",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan

AU - Twiggs, L. B.

AU - Morrow, C. P.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20%) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30%) had severe or life-threatening leukopenia with two of four (50%) complicated by septicemia. In Piver's group six of eight patients (75%) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.

AB - The efficacy of CTX as initial chemotherapy in advanced ovarian carcinoma has been well documented. Its apparently greater response rate when administered in a high-dose bolus has prompted its application to patients who have failed on melphalan. Piver et al. reported only one partial response lasting 1 month among seven patients with ovarian cancer refractory to alkylating drug therapy. Three of his patients had received low-dose CTX in combination with actinomycin D and 5-FU or methotrexate prior to receiving high-dose CTX. Although none of our patients had received prior CTX, the response rate was comparable (two of ten patients, 20%) with no complete responses. Toxicity from this drug regimen was considerable. In our study four of 13 patients (30%) had severe or life-threatening leukopenia with two of four (50%) complicated by septicemia. In Piver's group six of eight patients (75%) had severe leukopenia with five manifesting septicemia. It is clear that the risks of high-dose bolus CTX therapy for ovarian carcinoma resistant to melphalan outweigh the potential benefits.

UR - http://www.scopus.com/inward/record.url?scp=0017590062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017590062&partnerID=8YFLogxK

M3 - Article

C2 - 589602

AN - SCOPUS:0017590062

VL - 61

SP - 1369

EP - 1371

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -